405 related articles for article (PubMed ID: 32535060)
21. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
[TBL] [Abstract][Full Text] [Related]
22. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
23. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
[TBL] [Abstract][Full Text] [Related]
24. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
[TBL] [Abstract][Full Text] [Related]
25. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of measuring hepatic venous pressure gradient on transjugular liver biopsy for patients with pre-cirrhotic bridging fibrosis liver disease.
Vu T; Eberly H; Zheng A; Hintze A; McGillen KL; Cruz J; Shin B
Clin Imaging; 2023 Apr; 96():44-48. PubMed ID: 36801536
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
Jindal A; Sarin SK; Kumar M; Kumar G
Dig Dis Sci; 2022 Nov; 67(11):5280-5289. PubMed ID: 35113276
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.
Semmler G; Binter T; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Gavasso S; Chromy D; Bauer DJM; Simbrunner B; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Steindl-Munda P; Schöfl R; Russo FP; Simioni P; Trauner M; Ferenci P; Reiberger T; Mandorfer M
Hepatology; 2021 Apr; 73(4):1275-1289. PubMed ID: 32659847
[TBL] [Abstract][Full Text] [Related]
29. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study.
Jansen C; Bogs C; Verlinden W; Thiele M; Möller P; Görtzen J; Lehmann J; Vanwolleghem T; Vonghia L; Praktiknjo M; Chang J; Krag A; Strassburg CP; Francque S; Trebicka J
Liver Int; 2017 Mar; 37(3):396-405. PubMed ID: 27569696
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
[TBL] [Abstract][Full Text] [Related]
31. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
32. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
[TBL] [Abstract][Full Text] [Related]
33. [Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient].
Jiang FR; Yan HD
Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):995-1000. PubMed ID: 34814395
[No Abstract] [Full Text] [Related]
34. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
35. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T
Aliment Pharmacol Ther; 2017 Jan; 45(1):139-149. PubMed ID: 27910154
[TBL] [Abstract][Full Text] [Related]
36. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
37. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications.
Kitson MT; Roberts SK; Colman JC; Paul E; Button P; Kemp W
Scand J Gastroenterol; 2015 Apr; 50(4):462-9. PubMed ID: 25623641
[TBL] [Abstract][Full Text] [Related]
38. The impact of hepatic steatosis on portal hypertension.
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
[TBL] [Abstract][Full Text] [Related]
39. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
40. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.
Calvaruso V; Dhillon AP; Tsochatzis E; Manousou P; Grillo F; Germani G; Patch D; O'Beirne J; Burroughs AK
J Gastroenterol Hepatol; 2012 Jul; 27(7):1227-32. PubMed ID: 22432427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
